精準神經退化性疾病全球市場，2024-2028

Precision Neurodegenerative Disease Market, Global, 2024-2028

出版日期: 2024年08月26日 | 出版商:

Frost & Sullivan | 英文 75 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

將人工智慧能力、緩解疾病治療和產業相結合將推動精準 NDD 治療的變革性成長

全球神經退化性疾病（NDD）盛行率的上升正在推動從症狀治療轉向針對獨特病理機制（例如蛋白質錯誤折疊、發炎和突觸功能障礙）的緩解疾病治療的轉變，因此需要根據獨特的基因光譜客製化治療方法。 Precision NDD 正在改變臨床試驗設計，導致使用數位雙胞胎進行基於精確診斷的試驗和自適應小規模臨床試驗設計。專注於精準 NDD 的公司正在採用下一代生物資訊學、體學和藥物遺傳學來開發機制特異性的治療方法。神經類器官、表觀基因研究平台和生物資訊解決方案等研究工具可實現資料驅動的臨床和轉化研究。預測 NDD 風險的新型生物和數位生物標記以及遺傳變異的發現和檢驗是一項突破。基於人工智慧、機器學習、機器人技術和巨量資料的多組體學工具正在提高目標識別/檢驗的準確性，以減少臨床試驗失敗，這是 NDD 藥物研發的關鍵挑戰。表觀遺傳療法、主動免疫治療和蛋白水解療法等治療方法，以及定序伴同性診斷、神經影像學和單光子發射斷層掃描等精密模式，將用於精密NDD。奈米顆粒創新正在創造可以穿過血腦障壁的靶向藥物輸送解決方案。

涵蓋了全球精準 NDD 行業的進展，包括對影響 NDD 領域創新療法和平台採用的趨勢的分析。精準 NDD 產業正在經歷變革時期，整個醫藥價值鏈中精準醫療 (PH) 應用的整合，包括藥物發現和開發解決方案、標靶治療治療、監測和患者支持解決方案。見解包括阿茲海默症和帕金森氏症的行業概況和臨床實驗狀況、整體監管趨勢、不斷發展的治療方法的未來前景、PH 對手術干預的影響、數位醫療技術製藥融合等。它提供了對正在開發突破性技術、治療方法、生物標記和診斷成像進步的創新公司的見解，這些技術、治療方法、生物標記和診斷成像進步正在改變阿茲海默症和帕金森氏病的治療。製藥、診斷和醫療設備參與者之間的策略整合強調使用數位和醫療技術來檢測、管理和監測疾病進展並提供客製化治療，並可以填補 NDD 管理中的重要空白。這項研究服務確定了最受歡迎和新興的經營模式經營模式，有助於填補 NDD 管理方面的空白。這使得產業參與者能夠增強他們的競爭力、服務產品和地理推廣。它還透過確定關鍵的市場促進因素、限制因素、夥伴關係以及當前和未來的趨勢來解決患者獲取不足的挑戰。

NDD產業概況-產業現狀
開發平臺和產業概況 - AD
研發開發平臺和產業概況 - PD
AD臨床試驗現狀
臨床試驗狀態-PD
研發的主要挑戰－測試失敗率高
價值提案- 為什麼精準干預至關重要
PH在神經退化性疾病的應用
推動市場成長的趨勢
政府政策和監管趨勢
市場准入實施通訊協定
精準醫療價值鏈中的經營模式與夥伴關係
經營模式
夥伴關係影響
整合活動
前景

適應症使用案例—阿茲海默症

現狀與挑戰
盛行率和經濟負擔的預測
未滿足的核心需求和產業參與者的焦點
PM 應用中的新解決方案
趨勢與新技術-AD
特色企業

適應症使用案例－帕金森氏症

現狀與挑戰
盛行率和經濟負擔的預測
未滿足的核心需求和產業相關人員的焦點
PM 應用的新解決方案
產業趨勢及新技術-PD
值得關注的公司

成長機會宇宙

用於 RA、AD 和 PD 患者的 Growth Opportunity 1-GLP-1 胰島素製劑
成長機會2－基於神經技術的精準治療
成長機會3 - 罕見NDD的多目標策略
成長機會4－人工智慧在神經保護治療的整合
圖表列表
免責聲明

簡介目錄

Product Code: PFOO-52

Precision NDD Treatment is Experiencing Transformational Growth due to AI Capabilities, Disease-modifying Therapies, and Industry Convergence

The rising global prevalence of neurodegenerative diseases (NDDs) is driving the shift from symptom-to-disease-modifying therapeutics that target unique pathological mechanisms, such as protein misfolding, neuroinflammation, and synaptic dysfunction, and customizing treatment based on unique genetic profiles, disease subtypes, and distinct biomarkers. Precision NDD has changed clinical trial design, resulting in precision diagnostics-based studies and the use of digital twins for adaptive and small-sized clinical trial designs. Precision NDD-focused companies employ next-generation bioinformatics, omics, and pharmacogenetics to develop mechanism-specific therapy approaches. Precision research tools, such as neural organoids, platforms for pharmacoepigenomics studies, and bioinformatics solutions, enable data-driven clinical and translational research. The discovery and validation of novel biological and digital biomarkers, and genetic variants to predict NDD risk are breakthroughs. AI, ML, robotics, and big data-based multi-omics tools are improving the degree of precision for target identification/validation to limit clinical trial failures, a critical challenge for NDD drug R&D. Therapeutic approaches such as epigenetic therapy, active immunotherapies, protein degradation therapies, and precision modalities, such as sequencing companion diagnostics, neuroimaging, and single photon emission computed tomography, will be adopted for precision NDD. Innovations in nanoparticles are creating game-changing targeted drug delivery solutions that can cross the blood-brain barrier.

Advancements in the global precision NDD industry, including analysis relating to trends shaping the uptake of innovative therapeutics and platforms in the NDD landscape, are covered. The precision NDD industry is undergoing a transformative shift, driven by the integration of precision health (PH) applications across the pharmaceutical value chain, covering drug discovery and development solutions, targeted therapeutics, and monitoring and patient support solutions. Insights include an industry overview and clinical trial landscape of Alzheimer's disease and Parkinson's disease, prevailing regulatory trends, the future outlook of evolving therapeutic modalities, the impact of PH on surgical interventions, and digital-MedTech-Pharma convergence. Insights are provided into game-changing companies developing innovative technologies and treatment modalities, biomarkers, and imaging advancements that are transforming the management of Alzheimer's and Parkinson's diseases. Strategic integration among pharma, diagnostics, and medical device players is highlighted because the convergence of capabilities fills vital gaps in the management of NDDs by enabling the use of digital and MedTech technologies to detect, manage, and monitor disease progression and administer customized therapeutics. The research service identifies the most prevalent and emerging business models that help bridge the gaps in NDD management. This enables industry participants to enhance their competitiveness, service offerings, and geographic outreach. It also addresses the challenges of inadequate patient access by highlighting the primary market drivers, restraints, partnerships, and present and future trends.

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Precision Neurodegenerative Disease (NDD) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™